Effect of an Active vs Expectant Management Strategy on Successful Resolution of Pregnancy Among Patients With a Persisting Pregnancy of Unknown Location: The ACT or NOT Randomized Clinical Trial
- PMID: 34342619
- PMCID: PMC8335579
- DOI: 10.1001/jama.2021.10767
Effect of an Active vs Expectant Management Strategy on Successful Resolution of Pregnancy Among Patients With a Persisting Pregnancy of Unknown Location: The ACT or NOT Randomized Clinical Trial
Abstract
Importance: Women with an early nonviable pregnancy of unknown location are at high risk of ectopic pregnancy and its inherent morbidity and mortality. Successful and timely resolution of the gestation, while minimizing unscheduled interventions, are important priorities.
Objective: To determine if active management is more effective in achieving pregnancy resolution than expectant management and whether the use of empirical methotrexate is noninferior to uterine evacuation followed by methotrexate if needed.
Design, setting, and participants: This multicenter randomized clinical trial recruited 255 hemodynamically stable women with a diagnosed persisting pregnancy of unknown location between July 25, 2014, and June 4, 2019, in 12 medical centers in the United States (final follow up, August 19, 2019).
Interventions: Eligible patients were randomized in a 1:1:1 ratio to expectant management (n = 86), active management with uterine evacuation followed by methotrexate if needed (n = 87), or active management with empirical methotrexate using a 2-dose protocol (n = 82).
Main outcomes and measures: The primary outcome was successful resolution of the pregnancy without change from initial strategy. The primary hypothesis tested for superiority of the active groups combined vs expectant management, and a secondary hypothesis tested for noninferiority of empirical methotrexate compared with uterine evacuation with methotrexate as needed using a noninferiority margin of -12%.
Results: Among 255 patients who were randomized (median age, 31 years; interquartile range, 27-36 years), 253 (99.2%) completed the trial. Ninety-nine patients (39%) declined their randomized allocation (26.7% declined expectant management, 48.3% declined uterine evacuation, and 41.5% declined empirical methotrexate) and crossed over to a different group. Compared with patients randomized to receive expectant management (n = 86), women randomized to receive active management (n = 169) were significantly more likely to experience successful pregnancy resolution without change in their initial management strategy (51.5% vs 36.0%; difference, 15.4% [95% CI, 2.8% to 28.1%]; rate ratio, 1.43 [95% CI, 1.04 to 1.96]). Among active management strategies, empirical methotrexate was noninferior to uterine evacuation followed by methotrexate if needed with regard to successful pregnancy resolution without change in management strategy (54.9% vs 48.3%; difference, 6.6% [1-sided 97.5% CI, -8.4% to ∞]). The most common adverse event was vaginal bleeding for all of the 3 management groups (44.2%-52.9%).
Conclusions and relevance: Among patients with a persisting pregnancy of unknown location, patients randomized to receive active management, compared with those randomized to receive expectant management, more frequently achieved successful pregnancy resolution without change from the initial management strategy. The substantial crossover between groups should be considered when interpreting the results.
Trial registration: ClinicalTrials.gov Identifier: NCT02152696.
Conflict of interest statement
Figures
Comment in
-
Active vs Expectant Management of Persisting Pregnancy of Unknown Location.JAMA. 2021 Dec 14;326(22):2329-2330. doi: 10.1001/jama.2021.18405. JAMA. 2021. PMID: 34905038 No abstract available.
Similar articles
-
Methotrexate vs expectant management for treatment of tubal ectopic pregnancy: An individual participant data meta-analysis.Acta Obstet Gynecol Scand. 2023 Sep;102(9):1159-1175. doi: 10.1111/aogs.14617. Epub 2023 Jun 22. Acta Obstet Gynecol Scand. 2023. PMID: 37345445 Free PMC article. Review.
-
Optimal treatment for women with a persisting pregnancy of unknown location, a randomized controlled trial: The ACT-or-NOT trial.Contemp Clin Trials. 2018 Oct;73:145-151. doi: 10.1016/j.cct.2018.09.009. Epub 2018 Sep 20. Contemp Clin Trials. 2018. PMID: 30243810 Free PMC article.
-
Methotrexate or expectant management in women with an ectopic pregnancy or pregnancy of unknown location and low serum hCG concentrations? A randomized comparison.Hum Reprod. 2013 Jan;28(1):60-7. doi: 10.1093/humrep/des373. Epub 2012 Oct 18. Hum Reprod. 2013. PMID: 23081873 Clinical Trial.
-
Randomized comparison of health-related quality of life in women with ectopic pregnancy or pregnancy of unknown location treated with systemic methotrexate or expectant management.Eur J Obstet Gynecol Reprod Biol. 2015 Sep;192:1-5. doi: 10.1016/j.ejogrb.2015.06.007. Epub 2015 Jun 17. Eur J Obstet Gynecol Reprod Biol. 2015. PMID: 26125101 Clinical Trial.
-
Methotrexate versus expectant management in ectopic pregnancy: a meta-analysis.Arch Gynecol Obstet. 2022 Mar;305(3):547-553. doi: 10.1007/s00404-021-06236-y. Epub 2021 Sep 15. Arch Gynecol Obstet. 2022. PMID: 34524502 Review.
Cited by
-
β-Human Chorionic Gonadotropin Dynamics in Early Gestational Events: A Practical and Updated Reappraisal.Obstet Gynecol Int. 2024 Mar 7;2024:8351132. doi: 10.1155/2024/8351132. eCollection 2024. Obstet Gynecol Int. 2024. PMID: 38486788 Free PMC article. Review.
-
Development of a single-visit protocol for the management of pregnancy of unknown location following in vitro fertilization: a retrospective study.Hum Reprod. 2024 Mar 1;39(3):509-515. doi: 10.1093/humrep/deae002. Hum Reprod. 2024. PMID: 38265302 Free PMC article.
-
Expectant management versus systemic methotrexate in the management of persistent pregnancy of unknown location, a seven-year retrospective analysis.Arch Gynecol Obstet. 2024 Mar;309(3):1035-1041. doi: 10.1007/s00404-023-07332-x. Epub 2024 Jan 9. Arch Gynecol Obstet. 2024. PMID: 38194091
-
Spontaneous Pregnancy After Surgical Repair of Subseptate Uterus: A Case Report and Review of the Available Literature.Cureus. 2023 Aug 13;15(8):e43399. doi: 10.7759/cureus.43399. eCollection 2023 Aug. Cureus. 2023. PMID: 37706127 Free PMC article.
-
Methotrexate vs expectant management for treatment of tubal ectopic pregnancy: An individual participant data meta-analysis.Acta Obstet Gynecol Scand. 2023 Sep;102(9):1159-1175. doi: 10.1111/aogs.14617. Epub 2023 Jun 22. Acta Obstet Gynecol Scand. 2023. PMID: 37345445 Free PMC article. Review.
References
-
- National Institute for Health and Care Excellence (NICE) . Ectopic pregnancy and miscarriage: diagnosis and initial management. Updated November 2019. Accessed April 20, 2021. https://www.nice.org.uk/guidance/ng126 - PubMed